repatha mechanism of action
CLINICAL PHARMACOLOGY Mechanism of Action Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin 9 …  The FDA approved evolocumab injection on 27 August 2015, for some patients who are unable to get their LDL cholesterol under control with current treatment options. Mechanism of Action. Repatha®Mechanism of ActionRepatha®MOA Repatha®helps the liver clear LDL cholesterol by limiting the actions of a protein called PCSK9—and less PCSK9 means less LDL-C in the blood.1 Sign up for important Repatha®updates today Reference: 1. Evolocumab binds selectively to PCSK9 and prevents circulating PCSK9 from binding to the low density lipoprotein receptor (LDLR) on the liver cell surface, thus preventing PCSK9-mediated LDLR degradation. evolocumab Manufacturer: Amgen. restrictions. Mechanism of Action . Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia. Adding plans allows you to compare formulary status to other drugs in the same class. Please confirm that you would like to log out of Medscape. PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood. European drug market entries 2015 with new mechanisms of action. commonly, these are "non-preferred" brand drugs or specialty In the absence of PCSK9, there are more LDL receptors on the surface of liver cells to remove LDL-C from the blood. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. Take Action HOW DOES REPATHA ® WORK? mcg/mL (420 mg), At low concentrations: Elimination is predominately through saturable binding to target, PCSK9, At higher concentrations: Elimination of evolocumab is largely through a nonsaturable proteolytic pathway, Remove prescribed dose from refrigerator at least 30 minutes before administration; this helps administer the entire dose and minimizes injection discomfort, Do not heat syringe, autoinjector, or on-body infuser (eg, microwave or hot water); let them warm to room temperature on their own, Do not leave in direct sunlight; keep in original carton until administered, Available as 140-mg/mL prefilled syringe or autoinjector; also available as 420-mg/3.5-mL on-body infusor, 420 mg dose: Give three 140-mg SC injections consecutively within 30 minutes OR over 9 minutes using the single-use on-body infusor with refilled cartridge, Clean injection site with alcohol wipe and let dry, Do not inject in areas of skin that are bruised, red, tender, or hard, Avoid injecting in scars or stretch marks, See prescribing information for images depicting injection technique for the various devices, Refrigerate at 2-8°C (36-46°F) in the original carton, Alternatively, may store at room temperature (20-25°C [68-77°F]) in the original carton; however, under these conditions, drug must be used within 30 days; if not used within the 30 days, discard, Do not expose to temperatures >25°C (77°F). Distributor: Zuellig Pharma. If you log out, you will be required to enter your username and password the next time you visit. Repatha ® helps the liver clear LDL bad cholesterol by limiting the actions of a protein called PCSK9—and less PCSK9 means less LDL in your blood. PCSK9 binds to LDLR on the hepatocyte surface to promote LDLR degradation within the liver. Evolocumab (trade name Repatha) is a monoclonal antibody medication designed for the treatment of hyperlipidemia. Select item 27668060 4. , In 2015 it cost about US$14,100 per year. Share cases and questions with Physicians on Medscape consult. Individual plans may vary View the formulary and any restrictions for each plan. informational and educational purposes only. Evolocumab is a human monoclonal IgG2 antibody that binds to and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) binding to low-density lipoprotein receptors (LDLR). This drug is available at a middle level co-pay. Most Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, and Lp(a) from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p < 0.001) (see Table 2).
Blueberry Bliss Leave In Conditioner, Niger Seeds Online, Curls Blueberry Bliss Leave In Ingredients, Karpagam College Of Engineering Ranking, Ev 635a Used, New Single Story Homes In Roseville, Ca, Shoyu Poke Recipe, Online Cme Courses,